Abstract: Pure Sensory Neuropathy in Primary Sjögren's Syndrome. Longterm Prospective Followup and Review of the Literature

Pure Sensory Neuropathy in Primary Sjögren's Syndrome. Longterm Prospective Followup and Review of the Literature

JOSEP FONT, MANUEL RAMOS-CASALS, GLORIA de la RED, ADOLF POU, ARNAU CASANOVA, MARIO GARCÍA-CARRASCO, RICARD CERVERA, JOSÉ A. MOLINA, JOSEP VALLS, ALBERT BOVÉ, MIGUEL INGELMO, and FRANCESC GRAUS

ABSTRACT.

Objective. To study the clinical course, response to therapy, and longterm outcome of pure sensory neuropathy (PSN) in a series of patients with primary Sjögren's syndrome (SS) followed prospectively in our referral centers.

Methods. We studied 15 patients (13 women, 2 men) with primary SS and PSN. All patients fulfilled 4 or more of the European diagnostic criteria.

Results. At diagnosis of PSN, clinical manifestations included numbness and paresthesias (11 patients), trigeminal neuropathy (6 patients), and Adie's pupil syndrome (4 patients). In 7 patients, PSN was diagnosed prior to SS, in 5 the diagnoses were made simultaneously, and in the remaining 3 patients PSN was diagnosed after the appearance of SS symptomatology. The mean duration of the prospective PSN followup was 10 years (range 1–20). The progression of PSN was acute in 1 patient (producing severe dysfunction in less than 1 month), subacute in 3 patients, and in the remaining 11, the symptoms progressed slowly over the ensuing years to other extremities. Patients were treated with corticosteroids (n = 13), cyclophosphamide (n = 4), and intravenous immunoglobulins (n = 1), and 2 patients received no treatment. In spite of treatment, most patients showed an indolent and insidious longterm PSN course.

Conclusion. We found 3 differentiated clinical courses of the PSN in patients with primary SS: subacute progression in less than 1 month (7%), late acceleration of PSN 2–4 years after an initial indolent onset (20%), and a very longterm insidious, chronic evolution (73%). Prospective analysis of the longterm course of PSN shows a chronic and insidious evolution in most patients with PSN and SS, with a poor response to treatment, although stabilization of symptomatology for long periods is often observed. (J Rheumatol 2003;30:1552-7)

Key Indexing Terms:

PURE SENSORY NEUROPATHY
PRIMARY SJÖGREN'S SYNDROME

From the Department of Autoimmune Diseases and Department of Neurology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona; Department of Neurology, Hospital del Mar, Barcelona; Department of Internal Medicine, Hospital de Sabadell, Sabadell; and Department of Neurology, Hospital 12 de Octubre, Madrid, Spain.

J. Font, MD, PhD; M. Ramos-Casals, MD, PhD; G. de la Red, MD; M. García-Carrasco, MD, PhD; R. Cervera, MD, PhD; A. Bové, MD, PhD; M. Ingelmo, MD, PhD, Department of Autoimmune Diseases, University of Barcelona; A. Pou, MD, PhD, Department of Neurology, Hospital del Mar; A. Casanova, MD, PhD, Department of Internal Medicine, Hospital de Sabadell; J.A. Molina, MD, Department of Neurology, Hospital 12 de Octubre; J. Valls, MD, PhD; F. Graus, MD, PhD, Department of Neurology, University of Barcelona.

Address reprint requests to Dr. J. Font, Servei de Malalties Autoimmunes, Hospital Clínic, C/Villarroel 170, 08036 Barcelona, Spain. E-mail: jfont@clinic.ub.es

Submitted January 16, 2002; revision accepted November 27, 2002.